Sign in
TerminatedNo phase

Fluoroquinolone Resistance Prevalence Study

Key facts

Who runs it
Hackensack Meridian Health
Where
Hackensack and Washington D.C., United StatesSee the 2 sites
Trial code
Status
Terminated
People taking part
124 people enrolled
Started
8 Jul 2022
Ended
15 Jan 2025
Type of study
Observational
Record updated
5 June 2026
Why it stopped
Discontinued Recruitment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Subjects >18 yrs of age
  • Diagnosis of multiple myeloma undergoing (first or subsequent) autologous PBSC transplantation
  • Transplant conditioning with melphalan 200 mg/m2
  • PBSC cell dose of >2x10e6 CD34+ cells/kg
  • Able to receive fluoroquinolone prophylaxis
  • Subjects must give consent for enrollment into this study

Who cannot take part

  • Receiving a conditioning regimen other than melphalan 200 mg/m2
  • Unwillingness to provide informed consent
  • Enrollment into a treatment protocol prescribing antibiotic prophylaxis
  • A diagnosis other than multiple myeloma
  • Known light-chain amyloid deposition in any organ

Where in United States

  • John Theurer Cancer Center/ Hackensack Meridian HealthHackensack, United States
  • Lombardi Comprehensive Cancer Center, Georgetown UniversityWashington D.C., United States

About the trial

What the trial wants to find out

This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM).

Read full original descriptionShow less

These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploratory Study of Fluoroquinolone Resistance for Patients Undergoing Autologous Hematopoietic Stem Cell (HSC) Transplantation in the Treatment of Multiple Myeloma
Record updated
5 June 2026